Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.
about
Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload deliveryDual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable DomainImproving biophysical properties of a bispecific antibody scaffold to aid developabilityRecent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal AntibodiesImmunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsIdentification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activityAdvances in Antibody DesignDesign and applications of bispecific heterodimers: molecular imaging and beyondImmunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library ScreeningEngineered Autonomous Human Variable DomainsImproving target cell specificity using a novel monovalent bispecific IgG designFunctional assessment of antibody oxidation by native mass spectrometry.Computationally Designed Bispecific Antibodies using Negative State Repertoires.Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments.Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Acute myeloid leukemia targets for bispecific antibodies.Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion.Current progress in innovative engineered antibodies.Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.Structural basis of a novel heterodimeric Fc for bispecific antibody production.Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression systemHeavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry.Rapid characterization of biotherapeutic proteins by size-exclusion chromatography coupled to native mass spectrometryTriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.The making of bispecific antibodiesLC-MS characterization and purity assessment of a prototype bispecific antibody.8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.
P2860
Q26766713-B8B3C09E-6660-414E-9189-67AA264462AEQ27316983-3BBAF4CA-3736-44E9-970C-FC1F9B967C47Q27677540-2ADC0C74-FDBB-4020-98E6-4B322AC5E1A2Q27679445-431A7096-871D-4F87-881F-75CDFF557372Q28068946-50CC10C5-0E7A-40FE-A65E-EC55DAA431FFQ28072319-54AD110F-EA76-4089-9E32-2EE8A4F14513Q28487387-03678A84-1DCE-48B8-A1D0-B5A9C4DEC43DQ28817608-1AA8D4F0-B8D1-4F69-B889-CFBC45E803F4Q33732587-108390DB-1D55-4160-90F8-E545C679416FQ33781380-52EDE949-3328-4DAF-97E6-80E6966993B6Q33846405-B40A656F-6202-4195-85AD-5487F65B0DDBQ35119802-E3EB3E88-2260-4122-B926-1682E5850EEBQ35199371-4D91DF27-1E40-4073-B3B5-797DAF7F3BABQ35870955-4073D18E-0A4E-492F-9ACC-7819D48FC939Q36140177-B3C51FC4-B9AE-4091-AF3E-6060D6CB8E46Q36213090-60B541F0-2272-42FD-9D60-21F564FA613FQ36213342-EBB4EF25-7EB6-4555-9F7C-3B42ACDA73BBQ36899812-35E82632-A5AE-45AD-A44E-C5206980E14EQ37484229-EEDF43AC-BE40-41CD-B21A-EFA8A8DB66A0Q37496596-65726AB3-2D74-4E8B-A889-B3A994294153Q37563516-5E9FB665-6B25-46C6-B86E-7773FD77F63EQ37593702-03B8D808-C5E2-4263-BA63-D5C81A60F47BQ38706016-2A35AB8E-1881-4E7A-9C58-2D754EF50495Q38717942-DA70E225-B144-48C7-AD83-06820D6F5128Q38861238-1A3D66CF-ED47-43AC-BC8C-D31DEDB887CAQ38929801-3063F394-418C-4314-9BD2-44E4812490EDQ39117761-1AA257EF-3CCA-4D1D-90AE-91CDB4FC4027Q39836910-1A76D7C5-6BB2-4E95-B1D2-64FA2F604ED6Q40077818-C28754C7-C2E2-4C13-AEC0-EA08BA6F7573Q41489391-1C4F9C63-3B5A-4D06-8BF4-8A3ADB11DA3EQ41612592-2864D080-6475-4F39-BD52-BEF21FD10D58Q41647084-EE4551DA-93AC-448D-9450-4BBCDB429140Q41864920-62F8AB0E-B875-4B22-BF96-ADBCF3D41CE5Q41899683-F26E2E1A-1BDE-407B-8DC0-235C450F8ED9Q41901269-B910EDDF-3AD7-4593-A22A-F79701877790Q41924939-1C35D4E2-C2EA-44B0-BADF-B297037C2DD4Q42323236-4A032E94-E3CE-451E-882C-E65C8B30347BQ42846236-36A96DC2-7CCD-4F61-9CDB-B77CE0302BADQ42906644-668151A2-1F25-4C2D-B567-61FA2CAFD02FQ45037117-A6A0A0A8-1298-4A7F-A275-B1079AA115E8
P2860
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Progress in overcoming the cha ...... heterodimeric IgG antibodies.
@en
type
label
Progress in overcoming the cha ...... heterodimeric IgG antibodies.
@en
prefLabel
Progress in overcoming the cha ...... heterodimeric IgG antibodies.
@en
P2093
P2860
P356
P1476
Progress in overcoming the cha ...... c heterodimeric IgG antibodies
@en
P2093
Christian Klein
Claudio Sustmann
Hubert Kettenberger
Jürgen Schanzer
Kay Stubenrauch
Markus Thomas
Rebecca Croasdale
Ulrich Brinkmann
Wolfgang Schaefer
P2860
P304
P356
10.4161/MABS.21379
P577
2012-08-27T00:00:00Z